Safety and Efficacy of a Saquinavir-Containing Antiretroviral Regimen in Previously ART-Naïve or Pretreated but Protease Inhibitor-Naïve HIV-Positive Patients

[1]  D. Ward,et al.  Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults , 2009, Journal of acquired immune deficiency syndromes.

[2]  B. Yip,et al.  The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time , 2009, Journal of acquired immune deficiency syndromes.

[3]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[4]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[5]  M. Chesney,et al.  Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance , 2008, AIDS.

[6]  M. McKenna,et al.  Epidemiology of Human Immunodeficiency Virus in the United States , 2007, Clinical Microbiology Reviews.

[7]  B. Hirschel,et al.  Long-Term Efficacy and Safety of First-Line Therapy with Once-Daily Saquinavir/Ritonavir , 2007, Antiviral therapy.

[8]  J. Ananworanich,et al.  Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. , 2005, The Journal of antimicrobial chemotherapy.

[9]  B. Holmes,et al.  Saquinavir 500 mg Film-Coated Tablets Demonstrate Bioequivalence to Saquinavir 200 mg Hard Capsules When Boosted with Twice-Daily Ritonavir in Healthy Volunteers , 2005, Antiviral therapy.

[10]  B. Gazzard,et al.  A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial , 2005, Antiviral therapy.

[11]  L. Calza,et al.  Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[12]  Z. Fox,et al.  Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. , 2003, The Journal of infectious diseases.

[13]  A. Mocroft,et al.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.

[14]  J. Caylà,et al.  Impact of Adherence and Highly Active Antiretroviral Therapy on Survival in HIV‐Infected Patients , 2002, Journal of acquired immune deficiency syndromes.

[15]  M. Harris,et al.  Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy , 2002, HIV medicine.

[16]  Marilyn M. Wagener,et al.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .

[17]  F. Brun-Vézinet,et al.  Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen , 2002, AIDS.

[18]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[19]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[20]  M. Pérez-Elías,et al.  Percentage of Adherence Correlates with the Risk of Protease Inhibitor (PI) Treatment Failure in HIV-Infected Patients , 1998, Antiviral therapy.

[21]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.